Briefing Summary: US FDA Advisory Committee Posts Briefing Materials for Novartis’ FLUAD – SEP 15, 2015 (VRBPAC)

The US FDA has posted details, including Company and FDA Briefing Materials for the Tuesday, September 15, 2015 meetings of the Vaccines and Related Biological Products Advisory Committee (VRBPAC). The committee will meet in open session to discuss and make recommendations on the safety and immunogenicity of Seasonal Trivalent Influenza Vaccine, Surface Antigen, Inactivated, Adjuvanted with MF59 (FLUAD or aTIV) manufactured by Novartis. Note that, on July 31, 2015 the CSL Group and its Affiliates acquired the influenza vaccines business of Novartis AG in the US. The influenza vaccines business previously owned by Novartis is now referred to as NVS Influenza Vaccines.

See the SAC Tracker report